Survival rates for patients with glioblastoma (GBM) are abysmal, with median overall survival of approximately 15 months. Immunotherapy of GBM is a promising area of investigation, although challenges around identification of novel and immunogenic target antigens exist. IMA950 is a GBM specific vaccine comprising 11 tumor-associated peptides (TUMAPs) developed to address this challenge. We have performed a phase 1 safety and immunogenicity study in newly diagnosed GBM patients using IMA950 plus GM-CSF alongside standard of care chemo-radiotherapy. Our results demonstrate that IMA950 is well tolerated with 90% of patients having a CD8+ T-cell immune response to at least one TUMAP, with 50% responding to two or more TUMAPs. No effect of pre-treatment regulatory T-cell levels on IMA950 immunogenicity was found and steroids did not appear to affect immune responses to the TUMAPs. This data provides evidence to support further development and optimization of IMA950 together with other immunotherapies for GBM. were multi-TUMAP responders, with no important differences between cohorts. No effect of pre-treatment Treg levels on IMA950 immunogenicity was observed and steroids did not affect TUMAP responses. PFS was 74% at 6 months and 31% at 9 months. CONCLUSION: IMA950 plus GM-CSF was well tolerated with the primary immunogenicity endpoint of observing multi-TUMAP responses in at least 30% of patients exceeded.
Statement of Translational Relevance
Survival rates for patients with glioblastoma (GBM) are abysmal, with median overall survival of approximately 15 months. Immunotherapy of GBM is a promising area of investigation, although challenges around identification of novel and immunogenic target antigens exist. IMA950 is a GBM specific vaccine comprising 11 tumor-associated peptides (TUMAPs) developed to address this challenge. We have performed a phase 1 safety and immunogenicity study in newly diagnosed GBM patients using IMA950 plus GM-CSF alongside standard of care chemo-radiotherapy. Our results demonstrate that IMA950 is well tolerated with 90% of patients having a CD8+ T-cell immune response to at least one TUMAP, with 50% responding to two or more TUMAPs. No effect of pre-treatment regulatory T-cell levels on IMA950 immunogenicity was found and steroids did not appear to affect immune responses to the TUMAPs. This data provides evidence to support further development and optimization of IMA950 together with other immunotherapies for GBM.
Introduction
GBM, the most aggressive central nervous system tumor, develops from glial tissue of the brain and spinal cord (1) . Newly diagnosed GBM is an orphan disease with 100% mortality and a median overall survival (OS) of only 14.6 months (2). Standard first-line therapy comprises maximal safe tumor resection, followed by concomitant chemo-radiotherapy (radiotherapy plus daily temozolomide; CRT) and six 28-day cycles of adjuvant temozolomide (TMZ) (2) . Although the incidence is relatively low, around 3 to 4 cases per 100,000 population (3), GBM affects patients of all ages and there is a large unmet medical need for improved first-line therapy. Furthermore, there is evidence to suggest that the overall incidence of GBM is rising over time and will continue to increase in an ageing population (4, 5) .
IMA950 is an immunotherapeutic multiple-peptide vaccine specifically developed to treat GBM (6) . It contains 11 tumor-associated peptides (TUMAPs) that are presented by a majority of GBMs on human leukocyte antigen (HLA) surface receptors. IMA950 is designed to trigger the immune system by activation of TUMAP-specific cytotoxic T cells.
Once activated, these cells are postulated to find and destroy malignant tumor cells presenting the cognate TUMAPs. By vaccinating with 11 TUMAPs simultaneously there is an increased probability that a multi-clonal, broad yet highly specific T-cell response can be mounted against tumor cells thus hindering potential tumor escape mechanisms.
The primary objectives of this first time in human study were to assess the safety, tolerability and immunogenicity of IMA950 plus GM-CSF given alongside standard therapy in newly diagnosed GBM patients.
Patients and Methods

Patients
Eligible patients had histologically or cytologically proven GBM, an operable tumor which had already been maximally resected, were at least 18 years of age, human leukocyte antigen (HLA) A*02 positive and hepatitis B core antigen seronegative; had a World Health Organization (WHO) performance status 0 or 1, a life expectancy of at least 30 weeks and were expected to complete standard CRT and six 28 day cycles of adjuvant TMZ. Key exclusion criteria included: receipt of any prior GBM treatment apart from surgery, vaccination within 2 weeks or having taken dexamethasone at a dose >4 mg/day within 7 days prior to the first IMA950 plus GM-CSF vaccination, a history of serious cardiac or autoimmune disease or any condition which might interfere with the patient's ability to 
IMA950 Vaccine
IMA950 is a novel multi-peptide GBM specific vaccine comprising 11 HLA binding TUMAPs and one viral marker peptide, identified on HLA surface receptors in primary human GBM tissue, as described previously (6) . Supplementary Table S1 gives an overview of the TUMAP source antigens and their respective expression levels found in primary GBM tumor samples. Selected TUMAPs are designed to activate TUMAP-specific CD8+ cytotoxic and CD4+ helper T lymphocytes, which then recognize cognate TUMAPs presented by GBM tumor cells and effect a targeted immune response. Nine of the 11
TUMAPs were selected on the basis of their functional relevance, association with the human leukocyte antigen HLA-A*02, over-expression in GBM and proven immunogenicity using in vitro T-cell assays. The other two TUMAPs contained in IMA950 are both HLA class II-binding peptides designated IMA-BIR-002 and IMA-MET-005. IMA-BIR-002 has the capacity to activate CD4+ helper T cells (7) and potentially cytotoxic T lymphocytes (CTLs).
IMA-MET-005 contains a known HLA class I epitope, which was elongated based on the natural sequence of c-Met (known oncogene and potential marker of GBM stem cells (8) , with the capacity to activate helper T cells (9) and, after processing, CTLs). An additional non-TUMAP (IMA-HBV-001) was included in IMA950 derived from Hepatitis B virus (HBV) core antigen, to act as a positive control from a "non-self" antigen in cases where no vaccine-induced T-cell responses to TUMAPs from "self" antigens are observed.
Study Design and Treatment
Vaccination comprised fixed doses of recombinant granulocyte macrophage-colony stimulating factor (GM-CSF; 75 g), a commonly used immunomodulator (10), followed by IMA950 (4.96 mg, 413 g each peptide) injected intradermally (i.d.) at 11 time points over a 24 week period. All patients received the same vaccination schedule comprising an "Induction Phase" (VIP) of six intensive vaccinations (V1-V6), followed by a "Maintenance Phase" (VMP) of five vaccinations (V7-V11) over a longer period. Forty five patients with newly diagnosed GBM were entered into one of two Cohorts that differed by virtue of the first vaccination given at different time points alongside standard therapy (rationale for recruiting at least 20 patients per cohort is given in Supplementary Table S2 ). In Cohort 1, the VIP started 7 to 14 days before the scheduled onset of CRT to ensure that at least the 
Patient Monitoring and Assessment
The primary study endpoint of safety and tolerability was assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Disease was assessed using MacDonald criteria (11) with the secondary endpoint of progression free survival evaluated at 6 (PFS-6) and 9 months (PFS-9) from date of surgery. Any clinical complete (CR) or partial response (PR) to therapy was confirmed by an independent neuro-oncologist and radiologist. Although not an endpoint of the study, survival data was collected for two years after the final patient had received their first vaccination. The cut-off date for analysis was February 18, 2015.
Pharmacodynamic Analysis
A co-primary endpoint was determining the number of patients showing patient individual T-cell responses directed against TUMAPs contained in IMA950 at one or more post-vaccination time points, as determined by HLA multimer analysis (12, 13) . Individual patient peripheral blood mononuclear cell (PBMC) samples were pooled in order to ensure sufficient viable PBMCs for multimer analysis as follows: "Pre-vaccination" (PBMC samples 1 and 2), "post-vaccination 1" (PBMC samples 3 and 4), "post-vaccination 2" (PBMC samples 5 and 6) and "post-vaccination 3" (samples 7 and 8). See Supplementary Fig. S1 for further details. Tetramer staining for each TUMAP and control antigens were performed after an in vitro sensitization as described previously (13) . Exemplary gating is shown in Supplementary Fig. S2 . A positive vaccine-induced multimer CD8 T-cell response for any specific post-vaccination time point of a given antigen and patient was assigned if the following criteria were met: an above threshold immune response (assessed by five independent, trained and blinded jurors and according to Association for Cancer Immunotherapy recommendations (14) ) and an at least four-fold higher frequency of progression and pseudo-regression measured using a standardized diffusion-weighted (DWI) and perfusion-weighted (PWI) magnetic resonance imaging (MRI) protocol. Pseudoprogression was defined as an apparent increase in the enhancing tumor (>25%) on an early reference scan followed by a reduction in subsequent scans (assessed at Week 25 onwards), with no associated clinical deterioration. Pseudo-regression was assessed using an inverse definition. It was recommended that patients continue on therapy until the true clinical diagnosis was clarified. Although this design pre-dated that of recently published guidance, suggesting that patients continue the immunotherapy regimen for 3 months prior to PD confirmation (16) , it is generally in line with these recommendations.
Statistical Analysis
For the pharmacodynamic analysis, several different methods were used to calculate statistical significance depending on the type of data being examined. All statistical analysis was performed using Prism version 6.02 software (GraphPad Software Inc., La Jolla, California, USA). Two-tailed non-parametric Mann-Whitney test was used to determine differences between independent groups under examination. This included, for example, The Kaplan-Meier method was used to generate survival curves and estimate OS rates.
Log rank test was used to compare the survival distributions between groups of patients that included censored data.
Statistical analysis of imaging parameters was performed using a one-way ANOVA analysis with post hoc intergroup analysis using Tukey's test, due to a significant number of datasets being unavailable for analysis. Table 1 provides an overview of patient demographics. Of 138 patients screened, 53%
Results
Patient Demographics
were HLA-A*02 positive, which is in the expected range for a United Kingdom population (17) . Reasons for non-entry of 26 HLA-A*02 patients is given in Supplementary Table S3 .
Forty five patients were recruited into the study; 22 in Cohort 1 and 23 in Cohort 2. Forty patients were immune evaluable, with 39 evaluable for clinical activity assessment. This discrepancy is a result of two patients being lost for follow up between blood sample 6 and week 25 scan (see Supplementary Fig. S1 ), including one patient that was immune evaluable. The overall median age was 53 years (range 20-75 years) with no meaningful difference between cohorts. All patients had WHO performance status (PS) 0 or 1 at recruitment. A larger proportion of patients in Cohort 2 (65%) had a PS of 1 compared to Cohort 1 (27%), most likely due to Cohort 2 patients having undergone treatment with CRT.
As expected, the lymphocyte count on patient entry was lower in Cohort 2 (0.80x10 9 /L) compared to Cohort 1 (1.49x10 9 /L) reflecting the effect of concomitant TMZ in the former. 
Safety
All patients received at least one vaccination and were evaluated for safety (see Table 2 for the most commonly reported adverse events (AEs), regardless of causality). Injection site reaction (ISR) was the most frequent AE, and most common study drug related AE with 81 instances reported in 26 patients (12/22 patients in Cohort 1 and 14/23 patients in Cohort 2). The majority of ISRs were grade 1 (24 out of 26 patients) with only two instances of grade 2 events. Thirty one patients experienced at least one serious adverse event (SAE), one of which was a death unrelated to the study drug. The most frequently reported SAEs were seizure in 8 patients followed by thromboembolic events in 6 patients, none was study drug related. Investigators considered 4 SAEs to be related to the study drug including two cases of grade 4 neutrophil count decrease and one case each of grade 3 fatigue and anaphylaxis. The related SAEs of anaphylaxis and fatigue were both considered dose limiting toxicities. There were no unexpected differences in the safety profiles observed in the two cohorts.
Pharmacodynamics
Thirty six of 40 immune evaluable patients (90%) were TUMAP responders, with 20 (50%) responding to more than one TUMAP (Fig. 1A) . The pre-defined primary immunologic endpoint for recommending further development (≥60% single or ≥30% multi TUMAP responders) was therefore reached for the total immune evaluable study population and each of the two individual study cohorts. In Cohort 1, 9/19 (47%) evaluable patients responded to multiple TUMAPs, with a further 9 (47%) responding to a single TUMAP. There was no correlation between pre-treatment Treg levels and number of vaccine-induced TUMAP responses overall (Fig. 3A) or within either cohort of patients (Fig 3B and C) . A comparative analysis of study cohorts revealed that pre-treatment Treg levels normalized to lymphocytes were significantly increased (p=0.0003 by Wilcoxon test) in Cohort 2 compared to Cohort 1 (Fig. 3D ).
In order to explore possible effects of vaccination on observed pseudo-progression and pseudo-regression of disease, DWI and PWI was performed alongside standard gadolinium MRI scans. Cohort 1 patients showed increases in apparent diffusional coefficient (p<0.05), following CRT (see Supplementary Fig. S4 ). Over the same period, PWI parameters showed a trend (albeit not statistically significance) towards increased T1 values, contrast transfer coefficient (K trans ) and total enhancing volume (ve) with an associated decrease in plasma volume (vp) between scans 1 and 2 (data not shown).
Clinical Activity
Twenty nine of 39 evaluable patients were progression free at 6 months (PFS-6 of 74.4%) with 12 continuing to be progression free at 9 months (PFS-9 of 30.8%). Stable disease As of the cutoff date , median OS for the study was 15.3 months (Fig. 4A ) with no significant differences between the cohorts or those patients that responded to multiple TUMAPs compared to those that did not respond or to one TUMAP only (Fig. 4B) .
Interestingly, patients experiencing one or more ISRs had a significantly improved (p = 0.0001; hazard ratio 0.33) median OS of 26.7 months compared to 13.2 months for those that did not (Fig. 4C) . The median age of patients in the ISR group was significantly lower than that of the non-ISR (47 versus 57 years respectively; p = 0.023 by Mann Whitney test).
Imaging parameters in patients displaying ISRs showed no significant difference. However in Cohort 2 ISR was associated with lower K trans (p <0.05), vp (p<0.01), ve (p<0.05) and rate constant Kep (p<0.05) values at baseline.
Discussion
In the majority of treated GBM patients, IMA950 produced antigen specific peripheral CD8+ T-cell immune responses to the TUMAPs contained within the vaccine, with a relatively benign drug related toxicity profile comprising mainly minor injection site reactions. The two cohort study design was used to help define the most biologically effective and clinically feasible administration schedule of IMA950 for subsequent development as determined by the level of vaccine induced TUMAP specific immune responses for each schedule.
However, it does not allow direct comparison of clinical efficacy between cohorts since recruitment was not randomized nor was the trial prospectively powered to make such a comparison. Both cohorts presented challenges that had the potential to interfere with successful vaccination and the mounting of a measurable TUMAP specific immune response. In Cohort 1, there was a risk that CRT could be immunosuppressive (18, 19) and interfere with the induction and maintenance of TUMAP specific CD8+ T cells. Whereas in Cohort 2 there was the possibility that following completion of CRT, patient lymphocyte counts would be depleted and have lost the ability to mount a detectable immune response to IMA950. Indeed, immune data showed that Cohort 1 patients had a decreased detection rate of vaccine induced TUMAP responses at later time points (Fig. 2) , suggesting that CRT may interfere with the induction and maintenance of antigen specific CD8+ T cells. The greater number and improved durability of TUMAP responses in Cohort 2 suggests that lymphocyte depletion caused by CRT is either insufficient to hinder induction of antigen specific CD8+ T cells or can be recovered sufficiently rapidly to support their expansion.
Treg are a potent immunosuppressive cell population (20) that may interfere with the immunogenicity of cancer vaccines (21) . Given this, an additional key biological endpoint of this study was to explore the effect of pre-treatment Treg levels on the immunogenicity of IMA950. There was no correlation between pre-treatment Treg levels (relative to the overall lymphocyte population) and the number of vaccine induced TUMAP responses for the overall group of immune evaluable study patients. This result is similar to previous reports in other GBM vaccine studies (22, 23) . There was a significant increase in the Treg levels at the start of vaccinations in Cohort 2 compared to Cohort 1, likely indicating a relative increase of Treg compared to other lymphocyte subpopulations as a result of the preceding CRT (24) . The importance of this finding is unclear given that there were more vaccine-induced immune responses in Cohort 2.
The overall number of immune evaluable patients responding to multiple TUMAPs in this study (50%) exceeded that demonstrated for other similar vaccine products (13) such as IMA901, which had a multi-TUMAP response rate of 26%. In contrast to that found with IMA901, there was no apparent correlation between the number of TUMAP responses and improved survival (Fig. 4B) . However, there are key differences between this study and that of IMA901. IMA901 comprises different TUMAPs, selected specifically for the treatment of renal cell carcinoma (RCC) patients and the IMA901 study was conducted in the absence of potentially confounding standard of care therapy. Low dose cyclophosphamide (shown to decrease the number and function of Treg (25, 26) ) was also used alongside GM-CSF to further enhance immune response potential. In addition, RCC is known to be an immune-responsive tumor type (27) , whereas immunotherapy for GBM is still in its infancy.
Indeed, cancer vaccine immunotherapy strategies for GBM patients require considerable refinement due to the challenges posed by immune resistance and suppression in this tumor type (28) . Multiple immunosuppressive mechanisms are likely to be important in GBM including, enhanced secretion of immunosuppressive factors after exposure to standard therapy (29) , induction of tumor infiltrating lymphocytes and Treg activity (30) , as well as immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 (31, 32).
The aim of administering adjuvant(s) alongside therapeutic vaccines is to attempt to augment immune response and overcome immune suppression by either: moving the immune response toward Th1 or Th2 immunity, activating innate immunity or to serve as a local repository for prolonged antigen release and protection from degradation. In this study we utilized GM-CSF as an adjuvant based on the principle that it should enhance effective priming of T-cell responses (33, 34) and the fact that it had been successfully applied in late stage clinical trials (35) . There is evidence to suggest that in some circumstances at least, GM-CSF may not significantly enhance immune responses and may even be detrimental (36) . Even so, an earlier meta-analysis of published trials suggests that low-dose GM-CSF The observation that patients experiencing one or more ISRs had improved survival and were generally of younger age, suggest that ISR may be a prognostic marker for a patient population with an inherently healthier immune system (43) . This is supported by the significantly different imaging features in Cohort 2 patients experiencing ISRs whose tumors showed less vascularity and reduced angiogenesis associated vascular permeability.
Although this was an unplanned and retrospective analysis, a contribution of the vaccine to patient survival for those with a more vigorous immune system cannot be ruled out and could be investigated in future randomized studies that might include a non-specific immunogen. In addition, methylation of MGMT promoter conferred a survival advantage for GBM patients, as previously reported (44) .
A key factor that will need to be considered during the future development of IMA950 and therapeutic cancer vaccines more generally is the need to continue vaccination even after the disease appears to be progressing. Unlike conventional cancer chemotherapy, the effect of cancer immunotherapies is not directly on the disease but rather on the immune system which leads to a cellular immune response followed by tumoricidal biological activity and potentially improved patient survival (45) . This can lead to non-typical patient survival curves and misinterpretation of study results. Given this, chronic vaccination beyond disease progression, and potentially during subsequent therapy, will need to be carefully planned as part of future positioning alongside other therapy for the treatment of GBM.
IMA-HBV-001 was also included in the IMA950 vaccine to act as a positive control in cases where no vaccine-induced T cell responses to TUMAPs from "self" antigens are observed.
There was a trend (albeit not reaching statistical significance) for patients mounting an immune response toward IMA-HBV-001 also to respond to one or more TUMAP, supporting its use as a general immunogenicity marker. However these findings also suggest that IMA-HBV-001 has limited use as an independent control peptide for association analysis.
Successful development of effective therapeutic vaccines for cancer has proven to be particularly challenging. In the context of GBM, the most advanced therapeutic vaccine approach was that of rindopepimut (CDX-110) which consists a single 14-mer peptide derived from epidermal growth factor receptor variant III deletion mutation (EGFRvIII) (46) .
Results from a Phase II single arm study of rindopepimut, given to newly diagnosed EGFRvIII+ GBM patients post-CRT in combination with adjuvant TMZ, demonstrated a median OS of 21.8 months, an increase in anti-EGFRvIII antibody titer and clearance of EGFRvIII from the majority of analyzed post-treatment tumors (47) . Even so, the resulting pivotal, double-blind, randomized, Phase III trial using the same schedule and setting was terminated at a planned interim analysis due to emergent data indicating that the study would not reach statistical significance for the primary OS endpoint (48) . It is currently unclear as to why the study failed to meet the primary endpoint, albeit a median OS of 21. 
